Cheryl H. Arrowsmith

Cheryl H. Arrowsmith

SGC Toronto

Arrowsmith

Biography

Cheryl Arrowsmith is a Senior Scientist at the Princess Margaret Cancer Centre, Professor in the Department of Medical Biophysics, University of Toronto, and the Chief Scientist of the Structural Genomics Consortium (SGC) at the University of Toronto.  Her research focuses on the structural and chemical biology of chromatin and epigenetic regulatory factors especially as relates to cancer and drug discovery. In partnership with major pharmaceutical companies, she leads the SGC’s international open science program that is developing and distributing unencumbered Chemical Probes that support the discovery of new medicines. She received her Ph.D. from the University of Toronto and carried out postdoctoral research at Stanford University, and was co-founder of Affinium Pharmaceuticals, which developed a new medicine for multidrug resistant bacteria. She has published over 300 research articles and was recognized by Clarivate Analytics as being among the worlds top 1% of highly cited scientists in 2018, 2019 and 2022. She was elected an AAAS Fellow (2015), and a Fellow of the Royal Society of Canada (2020).

2011

Interferon-inducible protein 16: insight into the interaction with tumor suppressor p53.

Liao JC, Lam R, Brazda V, Duan S, Ravichandran M, Ma J, Xiao T, Tempel W, Zuo X, Wang YX, Chirgadze NY, Arrowsmith CH

Structure. 2011-3-9 . 19(3):418-29 .doi: 10.1016/j.str.2010.12.015

PMID: 21397192

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.

Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M, Marquez VE, Marra MA, Gascoyne RD, Humphries RK, Arrowsmith CH, Morin GB, Aparicio SA

Blood. 2011-2-24 . 117(8):2451-9 .doi: 10.1182/blood-2010-11-321208

PMID: 21190999

Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.

Shloush J, Vlassov JE, Engson I, Duan S, Saridakis V, Dhe-Paganon S, Raught B, Sheng Y, Arrowsmith CH

J. Biol. Chem.. 2011-2-11 . 286(6):4796-808 .doi: 10.1074/jbc.M110.157669

PMID: 21084285

Recognition and specificity determinants of the human cbx chromodomains.

Kaustov L, Ouyang H, Amaya M, Lemak A, Nady N, Duan S, Wasney GA, Li Z, Vedadi M, Schapira M, Min J, Arrowsmith CH

J. Biol. Chem.. 2011-1-7 . 286(1):521-9 .doi: 10.1074/jbc.M110.191411

PMID: 21047797

2010

Structural basis of E2-25K/UBB+1 interaction leading to proteasome inhibition and neurotoxicity.

Ko S, Kang GB, Song SM, Lee JG, Shin DY, Yun JH, Sheng Y, Cheong C, Jeon YH, Jung YK, Arrowsmith CH, Avvakumov GV, Dhe-Paganon S, Yoo YJ, Eom SH, Lee W

J. Biol. Chem.. 2010-11-12 . 285(46):36070-80 .doi: 10.1074/jbc.M110.145219

PMID: 20826778

Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.

Liu F, Chen X, Allali-Hassani A, Quinn AM, Wigle TJ, Wasney GA, Dong A, Senisterra G, Chau I, Siarheyeva A, Norris JL, Kireev DB, Jadhav A, Herold JM, Janzen WP, Arrowsmith CH, Frye SV, Brown PJ, Simeonov A, Vedadi M, Jin J

J. Med. Chem.. 2010-8-12 . 53(15):5844-57 .doi: 10.1021/jm100478y

PMID: 20614940

Biophysical characterization of recombinant proteins: a key to higher structural genomics success.

Vedadi M, Arrowsmith CH, Allali-Hassani A, Senisterra G, Wasney GA

J. Struct. Biol.. 2010-5-11 . 172(1):107-19 .doi: 10.1016/j.jsb.2010.05.005

PMID: 20466062

Pharmacophore screening of the protein data bank for specific binding site chemistry.

Campagna-Slater V, Arrowsmith AG, Zhao Y, Schapira M

J Chem Inf Model. 2010-3-22 . 50(3):358-67 .doi: 10.1021/ci900427b

PMID: 20112952

Structural biology of human H3K9 methyltransferases.

Wu H, Min J, Lunin VV, Antoshenko T, Dombrovski L, Zeng H, Allali-Hassani A, Campagna-Slater V, Vedadi M, Arrowsmith CH, Plotnikov AN, Schapira M

PLoS ONE. 2010-1-11 . 5(1):e8570 .doi: 10.1371/journal.pone.0008570

PMID: 20084102

2009

Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a.

Liu F, Chen X, Allali-Hassani A, Quinn AM, Wasney GA, Dong A, Barsyte D, Kozieradzki I, Senisterra G, Chau I, Siarheyeva A, Kireev DB, Jadhav A, Herold JM, Frye SV, Arrowsmith CH, Brown PJ, Simeonov A, Vedadi M, Jin J

J. Med. Chem.. 2009-12-24 . 52(24):7950-3 .doi: 10.1021/jm901543m

PMID: 19891491